Mr. Cedrone’s recent matters include the following:
- Co-authored prevailing merits briefs for the petitioner in Niz-Chavez v. Garland, 141 S. Ct. 1474 (2021), in which the Court limited the federal government’s ability to deny cancellation of removal to noncitizens. In a 6–3 decision, the Court adopted the petitioner’s argument that the government must serve a “notice to appear”—the document that triggers deportation proceedings and restricts a noncitizen’s eligibility for cancellation—as a single document containing all the required information, rather than as a series of individual notices with separate pieces of information.
- Co-authored successful merits briefs for the petitioner in the U.S. Supreme Court in Banister v. Davis, 140 S. Ct. 1698 (2020), in which the Court preserved certain procedural rights for criminal defendants seeking a writ of habeas corpus. In a 7–2 decision, the Court held that a timely filed Rule 59(e) motion to alter or amend the judgment in a federal habeas case is not an improper “second or successive” habeas petition.
- Briefed and argued a successful immigration appeal in the U.S. Court of Appeals for the Second Circuit. See Mendez v. Barr, 960 F.3d 80 (2020). The court reversed the Board of Immigration Appeals’ determination that misprision of a felony in violation of 18 U.S.C. § 4 is categorically a crime involving moral turpitude.
- Co-authored briefs successfully defending an antitrust class-action settlement in an appeal raising an issue of first impression regarding the authority of insurance claims administrators to opt customers out of class settlements. See In re Aggrenox Antitrust Litigation, 2020 WL 2146901 (2d Cir. 2020).
- Co-authored briefs in the D.C. Circuit securing dismissal of a challenge to a shipping client’s eligibility to participate in the federal Maritime Security Program. See Matson Navigation Co. v. U.S. Department of Transportation, 895 F.3d 799 (2018).
- Represented Braeburn in a successful lawsuit against the U.S. Food and Drug Administration. Co-authored summary-judgment briefing persuading the district court to vacate an exclusivity determination that blocked Braeburn’s new drug product BRIXADI™, a treatment for moderate to severe opioid use disorder, from receiving final approval. See Braeburn Inc. v. FDA, 389 F. Supp. 3d 1 (D.D.C. 2019).